Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance (original) (raw)

Summary

The syndrome of type A insulin resistance is encountered in young women and is characterized by glucose intolerance or frank diabetes mellitus, endogenous hyperinsulinism, insensitivity to insulin administration, acanthosis nigricans and virilization. The insulin resistance is due to reduced cellular insulin binding because of a lack of or defective binding sites and/or because the interaction with the tyrosine kinase of the β-subunit is hindered. This study was undertaken to find out whether hyperglycaemia in these patients may be influenced by the administration of recombinant human insulin-like growth factor I which exerts insulin like effects through the insulin receptor as well as the type 1 insulin-like growth factor I receptor. Recombinant human insulin-like growth factor I was intravenously administered in two subsequent doses of 100 μg/kg body weight to three women with type A insulin resistance. An immediate but slow fall of blood glucose was observed. The glucose disappearance rate was 28.0 μmol/min, i.e. considerably lower than that seen in healthy subjects. The markedly elevated insulin and C-peptide levels fell in a parallel manner to blood glucose but not to normal levels. The results show that recombinant human insulin-like growth factor I, presumably by reacting with the type 1 insulin-like growth factor receptor, can normalize serum glucose levels in patients with severe insulin resistance at least for several hours. We suggest that the potential of recombinant human insulin-like growth factor I to control hyperglycaemia in type A insulin resistant patients should be explored in more depth.

Article PDF

Similar content being viewed by others

References

  1. Kahn CR, Flier JS, Bar RS et al. (1976) The syndromes of insulin resistance and acanthosis nigricans. Insulin receptor disorders in man. N Engl J Med 294: 739–745
    PubMed Google Scholar
  2. Kahn CR, Podskalny JM (1980) Demonstration of a primary (genetic?) defect in insulin receptors in fibroblasts from a patient with the syndrome of extreme insulin resistance. J Clin Endocrinol Metab 50: 1139–1141
    PubMed Google Scholar
  3. Hedo JA, Moncada VY, Taylor SI (1985) Insulin receptor biosynthesis in cultured lymphocytes from insulin resistant patients. J Clin Invest 76: 2355–2361
    PubMed Google Scholar
  4. Moller DE, Flier JF (1988) Detection of an alteration in the insulin-receptor gene in a patient with insulin resistance, acanthosis nigricans and the polycystic ovary syndrome (Type A insulin resistance). N Engl J Med 319: 1526–1529
    PubMed Google Scholar
  5. Yoshimasa Y, Seino S, Whittaker J et al. (1988) Insulin-resistant diabetes due to a point mutation that prevents insulin proreceptor processing. Science 240: 784–787
    PubMed Google Scholar
  6. Taira M, Taira M, Hashimoto N et al. (1989) Human diabetes associated with a deletion of the tyrosine kinase domain of the insulin receptor. Science 245: 63–66
    PubMed Google Scholar
  7. Odawara M, Kadowaki T, Yamamota R et al. (1989) Human diabetes associated with a mutation in the tyrosine kinase domain of the insulin receptor. Science 245: 66–68
    PubMed Google Scholar
  8. Kadowaki T, Kadowaki H, Rechler MM et al. (1990) Five mutant alleles of the insulin receptor gene in patients with genetic forms of insulin resistance. J Clin Invest 86: 254–264
    PubMed Google Scholar
  9. Rinderknecht E, Humbel RE (1978) The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 253: 2769–2776
    PubMed Google Scholar
  10. Zapf J, Schoenle E, Froesch ER (1978) Insulin-like growth factor I and II: Some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulinlike activity of human serum. Eur J Biochem 87: 285–296
    PubMed Google Scholar
  11. Schoenle E, Zapf J, Humbel RE, Froesch ER (1982) Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature 296: 252–253
    PubMed Google Scholar
  12. Froesch ER, Schmid C, Schwander J, Zapf J (1985) Actions of insulin-like growth factors. Ann Rev Physiol 47: 443–467
    Article Google Scholar
  13. Salmon WD, Daughaday WH (1957) A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 49: 825–836
    PubMed Google Scholar
  14. Guler HP, Zapf J, Froesch ER (1987) Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317: 137–140
    PubMed Google Scholar
  15. Guler HP, Schmid C, Zapf J, Froesch ER (1989) Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 86: 2868–2872
    PubMed Google Scholar
  16. Froesch ER, Zapf J (1985) Insulin-like growth factors and insulin: comparative aspects. Diabetologia 28: 485–493
    Article PubMed Google Scholar
  17. Meuli C, Froesch ER (1977) Insulin and nonsuppressible insulinlike activity (NSILA-S) stimulate the same glucose transport system via two separate receptors in rat heart. Bioch Biophys Res Commun 75: 689–695
    Google Scholar
  18. Zapf J, Walter H, Froesch ER (1981) Radioimmunological determination of insulin-like growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycaemia. J Clin Invest 68: 1321–1330
    PubMed Google Scholar
  19. Zapf J, Schmid C, Guler HP et al. (1990) Regulation of binding proteins for insulin-like growth factors in humans. J Clin Invest 86: 952–961
    PubMed Google Scholar
  20. Poggi C, LeMarchand-Brustel Y, Zapf J, Froesch ER, Freychet P (1979) Effects and binding of insulin-like growth factor I in the isolated soleus muscle of lean and obese mice: comparison with insulin. Endocrinology 105: 723–730
    PubMed Google Scholar
  21. Zapf J, Schoenle EJ, Jagars G, Sand I, Grunwald J, Froesch ER (1979) Inhibition of the action of nonsuppressible insulin-like activity on isolated rat fat cells by binding to its carrier protein. J Clin Invest 63: 1077–1084
    PubMed Google Scholar
  22. Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541–548
    PubMed Google Scholar
  23. Polonsky KS, Given BD, Van Cauter E (1988) Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 81: 442–448
    PubMed Google Scholar
  24. Goldfine ID (1987) The insulin receptor: Molecular biology and transmembrane signalling. Endocrinol Rev 8: 235–255
    Google Scholar
  25. Becker AB, Roth RA (1990) Insulin receptor structure and function in normal and pathological conditions. Ann Rev Med 41: 99–115
    Article PubMed Google Scholar
  26. Abe H, Molitch ME, Van Wyk JJ, Underwood LE (1983) Human growth hormone and somatomedin C suppress the spontaneous release of growth hormone in unanesthetized rats. Endocrinology 113: 1319–1324
    PubMed Google Scholar
  27. Dunaif A, Segal K, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165–1174
    PubMed Google Scholar
  28. Froesch ER, Guler HP, Schmid C, Binz K, Zapf J (1990) Therapeutic potential of insulin-like growth factor I. Trends Endocrinology 1: 254–260
    Article Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Paediatrics, University of Zürich, Zürich, Switzerland
    E. J. Schoenle, T. Torresani, E. A. Werder & M. Zachmann
  2. Department of Medicine, University of Zürich, Zürich, Switzerland
    P. D. Zenobi & E. R. Froesch
  3. University Children's Hospital, Steinwiesstr 75CH-8032, Zürich, Switzerland
    E. J. Schoenle

Authors

  1. E. J. Schoenle
  2. P. D. Zenobi
  3. T. Torresani
  4. E. A. Werder
  5. M. Zachmann
  6. E. R. Froesch

Rights and permissions

About this article

Cite this article

Schoenle, E.J., Zenobi, P.D., Torresani, T. et al. Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance.Diabetologia 34, 675–679 (1991). https://doi.org/10.1007/BF00400998

Download citation

Key words